<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pretransplant screening to evaluate the risk of infection in hematopoietic cell transplant donors and candidates</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pretransplant screening to evaluate the risk of infection in hematopoietic cell transplant donors and candidates</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pretransplant screening to evaluate the risk of infection in hematopoietic cell transplant donors and candidates</div><div class="cntnt"><table cellspacing="0"><colgroup width="70%"></colgroup><colgroup span="2" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Tests and evaluations</td> <td class="subtitle1_left">Donor</td> <td class="subtitle1_left">Candidate<br/> (allogeneic or autologous)</td> </tr> <tr> <td><strong>History, review of systems, physical examination</strong></td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td><strong>Dental evaluation</strong></td> <td>–</td> <td>+</td> </tr> <tr> <td colspan="3"><strong>Radiology</strong></td> </tr> <tr> <td class="indent1">Chest radiograph or CT if history of prior pulmonary infection</td> <td>–</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td colspan="3"><strong>Pathogen-specific testing</strong></td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">CMV IgM and IgG</td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Hepatitis B (HBsAg, anti-HBsAg, anti-HBc) and viral load*</td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Hepatitis C (IgM, IgG)</td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Hepatitis C viral load<sup>¶</sup></td> <td>+</td> <td>–</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">VZV IgG</td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">HSV IgG</td> <td>–</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">EBV (VCA IgG)</td> <td>+</td> <td>+<br/> (especially allogeneic and T cell-depleted)</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">HIV-1, -2 screening test<sup>Δ</sup></td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">HIV-1 viral load</td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">HTLV-1, -2 antibodies</td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Syphilis screening test<sup>◊</sup></td> <td>+</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">West Nile virus NAT</td> <td>+</td> <td>–</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Serum <em>Aspergillus</em> galactomannan antigen<sup>§</sup></td> <td>–</td> <td>+/–</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1"><em>Toxoplasma gondii</em> IgG</td> <td>+</td> <td>+/–<br/> (allogeneic only, particularly T cell-depleted)</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Screening for TB<sup>¥</sup></td> <td>–</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1"><em>Staphylococcus aureus</em> nasal culture</td> <td>–</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Vancomycin-resistant <em>Enterococcus</em> rectal culture</td> <td>–</td> <td>+</td> </tr> <tr class="highlight_sub2_gray_text"> <td class="indent1">Respiratory viral multiplex panel, inclusive of SARS-CoV-2 PCR on nasopharyngeal swab specimen</td> <td>–</td> <td>+</td> </tr> <tr> <td colspan="3"><strong>Tests for individuals who have resided in or traveled to endemic areas</strong></td> </tr> <tr> <td class="indent1"><em>Strongyloides stercoralis</em> serology<sup>‡</sup></td> <td>–</td> <td>+</td> </tr> <tr> <td class="indent1"><em>Coccidioides</em> spp serology<sup>†</sup></td> <td>–</td> <td>+/–<br/> (especially allogeneic and T cell-depleted)</td> </tr> <tr> <td class="indent1"><em>Histoplasma capsulatum</em> serology<sup>†</sup></td> <td>–</td> <td>+/–<br/> (especially allogeneic and T cell-depleted)</td> </tr> <tr> <td class="indent1"><em>Trypanosoma cruzi</em> serology**<sup>,¶¶</sup></td> <td>+</td> <td>+/–</td> </tr> <tr> <td class="indent1">Malaria blood smears, rapid tests, and/or PCR<sup>ΔΔ</sup></td> <td>+</td> <td>+</td> </tr> <tr> <td class="indent1">Zika virus exposure history<sup>◊◊</sup></td> <td>+</td> <td>–</td> </tr> </tbody></table></div><div class="graphic_lgnd">The recommendations in this table are generally in keeping with the 2009 international guidelines for preventing infectious complications after hematopoietic cell transplantation<sup>[1]</sup>; some of our recommendations are not included in the guidelines.</div><div class="graphic_footnotes"><p>CMV: cytomegalovirus; Ig: immunoglobulin; HBsAg: hepatitis B surface antigen; anti-HBsAg: antibodies to hepatitis B surface antigen; anti-HBc: antibodies to hepatitis B core antigen; RT-PCR: reverse transcriptase polymerase chain reaction; HIV: human immunodeficiency virus; VZV: varicella-zoster virus; HSV: herpes simplex virus; EBV: Epstein Barr virus; HTLV: human T lymphotrophic virus; VDRL: venereal disease research laboratory; TB: tuberculosis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VCA: viral capsid antigen; CBC: complete blood count; PCR: polymerase chain reaction.</p>
<p>* All HCT donors who are either anti-HBc positive or HBsAg positive and all HCT candidates who are anti-HBc positive but negative for HBsAg and anti-HBs should undergo viral load testing for hepatitis B virus. Additional recommendations for the evaluation and management of HCT candidates in the setting of positive serologic or viral load testing results from the donor or recipient can be found in the 2009 international guidelines<sup>[1]</sup>.</p>
<p>¶ In addition to serologic testing for hepatitis C, all HCT candidates should undergo a careful history and physical examination for risk factors, signs, and symptoms of hepatitis C, as well as serum alanine aminotransferase (ALT) testing. Hepatitis C viral load testing should be performed in all HCT donors as well as in HCT candidates at increased risk for hepatitis C infection, including those who have received a transfusion with blood not tested for hepatitis C (eg, before 1992 in developed countries), history of IV or inhaled drug use, tattoos, or unexplained elevation of serum ALT. Viral load testing should also be performed in HCT candidates with positive hepatitis C serologic testing. Additional recommendations for the evaluation and management of HCT candidates in the setting of positive serologic or viral load testing results from the donor or recipient can be found in the 2009 international guidelines<sup>[1]</sup>.</p>
<p>Δ Refer to UpToDate text for detail on HIV screening test selection.</p>
<p>◊ Approach to screening test selection varies among institutions.</p>
<p>§ Serum <em>Aspergillus</em> galactomannan antigen testing should be performed in HCT candidates who have a past history of invasive aspergillosis and in others who are high-risk for invasive aspergillosis.</p>
<p>¥ Screening for TB includes obtaining a history of prior active TB or exposures to individuals likely to have TB, as well as results of previous tuberculin skin tests or interferon-gamma release assays.</p>
<p>‡ The southeastern United States is an endemic region; testing should therefore be performed in individuals who have resided in or traveled to this region. If <em>Strongyloides</em> antibody testing is not available or if active disease with strongyloidiasis is suspected in a seronegative HCT candidate, three stool samples should be sent for ova and parasites.</p>
<p>† Reactivation of endemic mycoses following HCT is very rare, even in endemic regions.</p>
<p>** Donors or recipients who were born, received a blood transfusion, or ever lived for six months or longer in a region that is endemic for Chagas disease (eg, parts of South and Central America and Mexico) should undergo serologic testing for <em>T. cruzi</em> IgG. Individuals who have lived for less than six months in an endemic are but who had high-risk living conditions (eg, lived in dwellings with mud walls, unmilled logs and sticks, or a thatched roof), should also undergo serologic testing. Individuals whose mother was born in an endemic region or who has a suggestive history (eg, cardiomegaly and dysrhythmias) should be screened due to the risk of congenital transmission. Since there is no gold standard for serologic testing, screening should be performed with at least two serologic tests (enzyme immunoassay, indirect hemagglutination, indirect fluorescent antibody, or radioimmunoprecipitation assay).</p>
<p>¶¶ <em>T. cruzi</em> antibody testing of HCT donors is required in some states in the United States.</p>
<p>ΔΔ Donors who have traveled to a malaria-endemic area should defer donation for one year following their return. Former or current residents of endemic areas should defer donation for three years. If this is not feasible, the donor should be treated empirically for malaria prior to donation. If the donor is diagnosed with active malaria, collection of stem cells should be delayed if possible until treatment has been completed and negative confirmatory testing obtained. If this is not feasible, preemptive treatment of the HCT recipient is reasonable, although there is no evidence regarding the safety or efficacy of this approach.</p>
◊◊ Potential HCT donors should be considered ineligible for HCT donation if they have been diagnosed with Zika virus infection over the past six months, resided in or traveled to an area with active mosquito-borne Zika virus transmission, or had sexual contact with a man who meets either of these criteria<sup>[3]</sup>. Potential umbilical cord blood donors should be considered ineligible for donation if the birth mother has been diagnosed with Zika virus infection at any point during the pregnancy, resided in or traveled to an area with active Zika virus transmission at any point during the pregnancy, or had sexual contact at any point during the pregnancy with a man who meets either of these criteria.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</li>
<li>US Food and Drug Administration. Testing HCT/P donors: Specific requirements. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/testing-donors-human-cells-tissues-and-cellular-and-tissue-based-products-hctp-specific-requirements (Accessed July 19, 2023).</li>
<li>US Food and Drug Administration. Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry, March 2016. Updated May 2018. <a href="https://www.fda.gov/media/96528/download" target="_blank">https://www.fda.gov/media/96528/download</a>. (Accessed July 19, 2023).</li>
</ol></div><div id="graphicVersion">Graphic 56453 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
